November 1st 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Headed to ARVO? You’re invited to dinner COPE CE/CME. Or join virtually!
May 6 & 7, 2024
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
The Ins and Outs of Lubricating Eye Drops
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Glaucoma agent lowers IOP by dual mechanism
February 1st 2005New Orleans—Travoprost 0.004% (Travatan, Alcon Laboratories) lowers IOP by both increasing outflow facility and improving uveoscleral outflow, according to the results of a clinical study designed to investigate the mechanism of action of travoprost.
Read More
Studies confirm utility of fixed-combination glaucoma drug
February 1st 2005New Orleans—Twice-daily administration of a fixed-combination product containing brimonidine 0.2% plus timolol 0.5% (Combigan, Allergan Inc.) safely and effectively lowers IOP, according to the pooled results of two 12-month, randomized, double-masked, phase III studies.
Read More
Ocular bioavailability of glaucoma drug improves with new formulation
February 1st 2005Timolol maleate ophthalmic solution 0.5% (Istalol, ISTA Pharmaceuticals), available in a new, once-a-day formulation, is as effective as a standard 0.5% timolol maleate ophthalmic solution administered twice daily to treat elevated IOP in ocular hypertension and open-angle glaucoma.
Read More
Fixed-combination drug yields superior IOP lowering
February 1st 2005New Orleans—Results of a prospective, randomized, double-masked study demonstrate a fixed combination of travoprost 0.004% and timolol 0.5% (Extravan, Alcon Laboratories) administered once daily is safe, well-tolerated, and offers better IOP lowering than monotherapy using either of its components, said Howard S. Barnebey, MD.
Read More
Advances provide sustained drug release for retinal disease
February 1st 2005Baltimore—Innovative pharmaceutical delivery systems are showing promise for their potential to provide safe and effective "site-directed" therapy for retinal diseases, said Eugene de Juan Jr., MD, in the Ronald G. Michels Memorial Lecture at the Current Concepts of Ophthalmology meeting.
Read More
Cytoskeletal agents: future option for reducing IOP?
February 1st 2005New Orleans—Cytoskeletal agents, which increase outflow facility in the trabecular meshwork, are one of the drug classes that could expand the pharmaceutical options available to reduce IOP, said Carl B. Camras, MD, professor, chairman, and director of the glaucoma service, department of ophthalmology, University of Nebraska Medical Center, Omaha.
Read More
New viscous-dispersive viscoelastic found promising
January 15th 2005Poughkeepsie, NY—DisCoVisc, a new viscous-dispersive ophthalmic viscosurgical device (OVD) from Alcon Laboratories, performed comparably to Healon in a randomized, FDA phase III clinical trial in key measurements such as endothelial cell density and IOP control, according to Satish Modi, MD.
Read More
Trial to study potential MMD treatment
January 1st 2005Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.
Read More
Retinal prosthesis development continues on positive path
January 1st 2005Los Angeles-A clinical trial of a prototype intraocular retinal prosthesis continues to produce encouraging results during ongoing follow-up. Meanwhile, the development program is on schedule for a higher-density device that investigators hope will enable unaided mobility for totally blind individuals, according to Mark S. Humayun, MD, PhD.
Read More
Trial to study potential MMD treatment
January 1st 2005Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.
Read More
Eye rinses recalled over sterility concerns
January 1st 2005Albany, OR-Alternative Health & Herbs Remedies is conducting a voluntary recall of all lots of four American Health & Herbs Ministry-brand eye rinse products following an FDA ruling that its manufacturing conditions were insufficient to produce a sterile product.
Read More
WaveLight captures 20% of U.S. laser sales
December 1st 2004Sterling, VA-WaveLight's chief executive officer said the company has achieved its greatest accomplishment to date by capturing 20% of all new refractive laser sales in the United States during the last 12 months with its Allegretto Wave.
Read More
Conflict-of-interest rules stiffen for CME activity
November 15th 2004Are ophthalmologists and other physicians who have financial relationships with pharmaceutical companies incapable of unbiased work in CME activity? Or, are those who believe any physician-regardless of income sources-can have unfettered, impartial teaching phi-losophies just kidding themselves as to the reality of the medical market place?
Read More
Anecortave acetate endpoint not met, but results similar to PDT
November 15th 2004New Orleans-The C-01-99 phase III clinical trial of anecortave acetate for depot suspension (Retaane, Alcon Laboratories Inc.) found that the drug did not meet the primary endpoint of non-inferiority to verteporfin (Visudyne, Novartis Ophthalmics and QLT Inc.) in the treatment of neovascular age-related macular degeneration (AMD).
Read More
Low-dose pegaptanib sodium offers improved visual acuity
November 15th 2004New Orleans-The VEGF (vascular endothelial growth factor) Inhibition Study in Ocular Neovascularization (VISION), a phase III appraisal of three doses of pegaptanib sodium injection (Macugen, Eyetech Pharmaceuticals), found that the 0.3-mg dose of the drug improves visual outcomes in patients with age-related macular degeneration (AMD) compared with a sham procedure and usual care (photodynamic therapy [PDT]).
Read More
Extension study reveals safety, durability of ranibizumab
November 15th 2004New Orleans-Two phase III trials, one phase II trial, and one extension trial are under way for anti-VEGF agent, ranibizumab (Lucentis, Genentech). The extension trial indicates that ranibizumab provides a long-term benefit to patients and that it is well tolerated, according to Jeffrey S. Heier, MD, who described the studies during the retina subspecialty day here at the American Academy of Ophthalmology annual meeting.
Read More
Implantable telescope may help patients with bilateral macular degeneration
October 24th 2004An implantable miniature telescope (IMT, VisionCare Ophthalmic Technologies Inc.) may help improve visual acuity in patients with bilateral, end-stage macular degeneration, according to the phase II/III results at 6 months.
Read More
Anecortave acetate results not significantly different from PDT
October 22nd 2004The C-01-99 phase III clinical trial, which compared a 15-mg dose of anecortave acetate (Alcon Laboratories) with standard administration of verteporfin for the treatment of neovascular age-related macular degeneration (AMD), found that there was no statistical difference between the two treatments.
Read More
Macugen demonstrates good visual results after 24 months
October 22nd 2004The VEGF (vascular endothelial growth factor) Inhibition Study in Ocular Neovascularization (VISION), a phase III appraisal of three doses of pegaptanib sodium injection (Macugen, Eyetech Pharmaceuticals) (0.3, 1, and 3 mg) compared with a sham procedure, found that the 0.3-mg dose of Macugen improves visual outcomes in patients with age-related macular degeneration.
Read More